The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.
المخرجات
Research outputs
Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.
Brucellosis is a significant zoonotic disease caused by intracellular, gram-negative bacteria from the genus Brucella. Although camels are classified as secondary hosts for Brucella species, they are among the most susceptible and vulnerable animals to brucellosis, particularly Brucella abortus (B. abortus) and Brucella melitensis (B. melitensis). The present study aimed to investigate the epidemiology of camel brucellosis as a zoonotic disease by determining the seroprevalence of brucellosis in both camels and humans, assessing potential risk factors (e.g., age, size, and location), and conducting molecular characterization of Brucella spp. associated with abortion in camels. The Rose Bengal Test (RBT), Antigen Rapid Brucella Antibody Test (ARBT), indirect enzyme-linked immunosorbent assay (I-ELISA), and complement fixation test (CFT) were used to detect brucellosis in both camels and humans. Additionally, a molecular method using polymerase chain reaction was used as a confirmatory technique. A total of 625 camel serum samples and 100 human serum samples were collected in sterile vacuum tubes from various camel farms and individuals across different localities in the Al Qassim region. Additionally, samples from 10 confirmed Brucella-infected camels (including the uterus and supramammary lymph nodes) were analyzed. The results indicated that the overall prevalence of brucellosis in camel sera was 9.72%, as determined by RBT, and 8.16%, as determined by ARBT. In contrast, the overall prevalence of brucellosis in human sera from febrile patients was found to be 17% via RBT. Notably, 57.98% of camel sera that tested positive for Brucella antibodies via RBT were also positive according to I-ELISA and CFT. Furthermore, 42.1%, 70.58%, and 47.05% of human sera that were positive for Brucella antibodies as determined by RBT were also positive according to I-ELISA and CFT, respectively. The highest seropositivity for camel brucellosis was observed in female camels, particularly in the Unaizah area of the Qassim region and among the Homr breed. The prevalence of human brucellosis was highest among females and individuals who consumed raw milk. At the molecular level, B. melitensis biovar 3 was detected in the examined tissues. In conclusion, intervention measures are vital for reducing brucellosis in humans and camels. Public awareness campaigns should highlight the importance of protective clothing when handling aborted she-camels and the need to boil or pasteurize milk. Additionally, studies should differentiate between vaccinated and nonvaccinated camels, and standardizing serological tests for diagnosing brucellosis should be prioritized.
Archiv der Pharmazie · vol. 358 (7) · e70042-e70042
ABSTRACT A series of thiadiazole‐based derivatives were synthesized and evaluated for their potential as VEGFR‐2 inhibitors and anticancer agents. Among them, compound 7b demonstrated significant cytotoxic activity against MCF‐7 breast cancer cells, with an IC 50 value of 6.13 µM, surpassing that of the reference drug sorafenib (IC 50 : 7.26 µM). Compound 7b also exhibited potent VEGFR‐2 inhibition with an IC 50 of 40.65 nM, outperforming sorafenib (IC 50 : 53.32 nM). Further investigation into the mechanism of action revealed that compound 7b induced significant changes in the cell‐cycle distribution of MCF‐7 cells, causing G1 arrest and delaying progression through the G2/M phase. Apoptosis analysis demonstrated that compound 7b primarily induced late apoptosis (55.90%) and necrosis (21.81%), with only 22.26% of cells remaining viable. Treatment with 7b increased the expression of the proapoptotic gene BAX (4.19 ± 0.34‐fold) and suppressed the expression of the antiapoptotic gene Bcl‐2 (0.38 ± 0.02‐fold), resulting in a dramatic increase in the BAX/Bcl‐2 ratio (11.03 ± 1.66‐fold). Additionally, caspase‐8 and caspase‐9 levels were elevated by 2.99 ± 0.22‐fold and 4.13 ± 0.11‐fold, respectively, confirming activation of both intrinsic and extrinsic apoptotic pathways. In conclusion, compound 7b is a potent VEGFR‐2 inhibitor with promising anticancer activity, demonstrating cytotoxicity, inhibition of cell migration, and induction of apoptosis in MCF‐7 cells. These results suggest that compound 7b has the potential to be developed as a therapeutic agent for breast cancer treatment, warranting further in vivo and mechanistic studies.
thiadiazole derivativesVEGFR-2 inhibitorsanticancer agentsbreast cancer
Journal of Taibah University for Science · vol. 19 (1)
Bimetallic nanoparticles (BNPs) have gained immense attention for their diverse biological applications. This study aimed to biosynthesize and characterize Ag-ZnONPs and Fe-ZnONPs and compare their potential as therapeutic agents. The BNPs were synthesized using Mentha asiatica plant extract and characterized using various techniques such as UV-visible spectroscopy, TEM, EDX spectroscopy, ATR-FTIR spectroscopy, PXRD, DLS, and zeta potential analyses. TEM, EDX, and XRD revealed the structural and morphological properties of crystalline Ag-ZnONPs and Fe-ZnONPs. FTIR analysis investigated the plant phytochemicals responsible for the stabilization and capping of BNPs. Ag-ZnONPs showed higher biocompatibility than Fe-ZnONPs. Fe-ZnONPs exhibited-significantly higher anticancer potential than Ag-ZnONPs as evident by Reactive Oxygen Species/ Nitric Oxide Synthase production, along with cell viability analysis, loss of mitochondrial-membrane potential, enhanced caspase-3 gene-expression, and intensified activity of Caspase-3/7. Collectively, our findings underscore the promising therapeutic-potential of BNPs in cancer treatment and diabetes, setting them as strong candidates for future biomedical applications.
Lipids in Health and Disease · vol. 24 (1) · 109-109
BACKGROUND: Hypertriglyceridemia is an independent risk factor for cardiovascular diseases. In previous trials, apolipoprotein C-III (APOC3) inhibition through the antisense oligonucleotides volanesorsen, olezarsen, and plozasiran reduced triglyceride levels. However, the three medications' safety and efficacy have yet to be compared. METHODS: A network meta-analysis was performed to compare multiple doses of the three medications to each other through the placebo. Randomized controlled trials (RCTs) were retrieved by searching PubMed, EMBASE, Web of Science, SCOPUS, and Cochrane until November 22nd, 2024. The mean difference (MD) and 95% confidence interval (CI) were used for continuous outcomes. The risk ratio (RR) and 95% CI were used for dichotomous outcomes. RESULTS: Ten RCTs with a total of 1,129 patients were included. volanesorsen 300 mg once weekly showed the most significant percent reduction in triglyceride levels (MD = -91.0%, 95% CI: (-109.2%; -72.8%); P < 0.01). Only plozasiran once monthly, regardless of the dose, showed a non-significant percent reduction in triglycerides. This finding should be taken cautiously as the data were derived from a phase 1 trial with a small sample size. All the regimens significantly reduced APOC3 levels compared to placebo, with plozasiran 100 mg monthly and volanesorsen 300 mg once weekly showing the most significant reduction (MD range: -92.8% to -88.5%; P < 0.01). None of the treatments showed a statistically significant difference in overall adverse events rate compared to the placebo. CONCLUSION: APOC3 antisense oligonucleotide inhibitors effectively reduced triglyceride and APOC3 levels in hypertriglyceridemia with an acceptable safety profile. However, the results should be interpreted cautiously due to the small sample size. Further research is needed to confirm the beneficial effects of APOC3 inhibitors and show strong evidence of the impact of each regimen.
ADMET analysis predicted a favorable safety profile over sorafenib, particularly with respect to carcinogenic and chronic toxicity risks. These findings indicate that quinoxaline derivative 11d holds potential as a selective and effective VEGFR-2 inhibitor with promising antitumor and anti-metastatic properties, warranting further investigation.
Frontiers in Bioengineering and Biotechnology · vol. 13 · 1571066-1571066
Urine-based therapy, an ancient practice, has been utilized across numerous civilizations to address a wide range of ailments. Urine was considered a priceless resource in numerous traditional therapeutic applications due to its reported medicinal capabilities. While the utilization of urine treatment is contentious and lacks significant support from modern healthcare, the discovery of urine-derived stem cells (UDSCs) has introduced a promising avenue for cell-based therapy. UDSCs offer a noninvasive and easily repeatable collection method, making them a practical and viable option for therapeutic applications. Research has shown that UDSCs contribute to organ preservation by promoting revascularization and decreasing inflammatory reactions in many diseases and conditions. This review will outline the contemporary status of UDSCs research and explore their potential applications in both fundamental science and medical practice.
Journal of Infection and Public Health · vol. 18 (6) · 102763-102763
Leprosy and tuberculosis caused by Mycobacterium leprae and Mycobacterium tuberculosis, respectively, are chronic infections with significant public health implications. While leprosy affects the skin and peripheral nerves and tuberculosis primarily targets the lungs, both diseases involve systemic immune responses. This study integrates transcriptomic analysis cheminformatics and molecular dynamics simulations to identify molecular mechanisms and potential therapeutic targets. Transcriptomic datasets were analyzed to identify dysregulated genes and pathways. Pathway enrichment tissue-specific and bulk RNA-seq expression analyses provided biological context. System biology networks revealed regulatory hub genes and molecular docking studies evaluated CHEMBL compounds as potential therapeutics. Molecular dynamics (MD) simulations assessed the stability of top ligand-protein complexes through RMSD RMSF and MM-GBSA free energy calculations. Gene expression analysis identified 13 core dysregulated genes, including HSP90AA1 MAPK8IP3 and ZMPSTE24. Tissue-specific expression localized pivotal genes to lung tissues and immune cells with HSP90AA1 highly expressed in alveolar macrophages and epithelial cells. HSP90AA1 gene emerged as a central hub gene with 96 interactions involved in stress response pathways. Docking studies identified CHEMBL3653862 and CHEMBL3653884 with strong binding affinities (-10.16 to −12.69 kcal/mol) interacting with Asp93 and Tyr139. MD simulations confirmed binding stability with RMSD fluctuations within 2.1–3.5 Å and MM-GBSA energy values supporting ligand-protein stability. This study identifies HSP90AA1 as a potential drug target in leprosy and tuberculosis. Findings support host-directed therapy approaches and highlight the importance of computational modeling in accelerating drug discovery. The study provides a foundation for future experimental validation, including in vitro and in vivo testing to advance drug repurposing strategies for these chronic infections. • Identified 13 shared dysregulated genes between tuberculosis and leprosy. • Uncovered critical pathways and protein-protein interactions using network medicine. • Highlighted roles of genes in immune-related cells through tissue-specific and single-cell gene expression analyses. • Conducted drug repurposing analysis, identifying CHEMBL compounds with strong binding affinities for key targets. • Deliver a comprehensive understanding of disease mechanisms and therapeutic opportunities.
Frontiers in Pharmacology · vol. 16 · 1507009-1507009
Background: Metformin, hypoglycemic medication, is recognized for its diverse properties and its capacity to influence the inflammatory pathways. Medications with anti-inflammatory and anti-oxidative characteristics have been demonstrated to be able to elicit and sustain remission in ulcerative colitis (UC), chronic inflammatory disorder of the bowel. Studies in both preclinical and clinical settings have looked into the several metabolic pathways via which metformin protects against UC. Aim: To assess efficacy of metformin as adjunctive therapy in patients with mild to moderate UC. Methods: This clinical research was double-blinded, randomized, controlled, and involved 60 patients with mild to moderate UC. The participants were randomly assigned to one of two groups (n = 30). The control group was given 1 g of mesalamine three times a day (t.i.d.) for a period of 6 months (mesalamine group). The metformin group was given 500 mg of metformin twice daily and 1 g of mesalamine t. i.d. For a period of 6 months. Patients with UC were assessed by a gastroenterologist using the disease activity index (DAI) both at the beginning of treatment and 6 months thereafter. To evaluate the drug's biological efficacy, measurements of fecal calprotectin, serum C-reactive protein (CRP), interleukin 10 (IL-10), and nitric oxide (NO) were taken both before and after treatment. Study outcomes: Decrease in DAI and change in the level of measured serum and fecal markers. Results: = 0.04) when compared to the mesalamine group. There was a significant direct correlation between DAI and calprotectin (p < 0.0001, r = 0.551), and between DAI and CRP (p < 0.0001, r = 0.794). There was a significant negative correlation between DAI and IL-10 (p = 0.0003, r = 0.371). Conclusion: Metformin may be an effective adjunct drug in management of patients with mild to moderate UC by decreasing DAI and other inflammatory markers that were involved in the pathogenesis of UC. Clinical Trial Registration: identifier NCT05553704.
The Fédération internationale de football association (FIFA) 11 + warm-up program, initially tailored for soccer, has gathered attention for its effectiveness in reducing injury rates and enhancing performance in soccer players. This study aimed to compare the effects of an 8-week FIFA 11 + warm-up program with a conventional warm-up on injury prevention, performance, and fitness parameters in professional male cyclists. Eighty professional male cyclists, aged between 18 and 45 years and actively engaged in cycling activities, were included in this study. Pre-and post-intervention assessments following a structured 8-week warm-up program based on the FIFA 11 + protocol covered a range of performance and fitness parameters, including agility (T-test), flexibility (V Sit and Reach test), lower limb explosive power (Broad Jump test), cycling speed (3-kilometer cycling test), core muscle strength (plank tests), balance (Open and Closed Eyes tests), and exercise tolerance (Rate of Perceived Exertion or RPE), and injury incidence rates. Both warm-up programs showed improvements in agility, flexibility, lower limb explosive power, and 3-kilometer cycling performance. However, the FIFA 11 + program exhibited significantly greater enhancements in core muscle strength, balance, and exercise tolerance, as indicated by reduced perceived exertion, and injury reduction compared to the conventional warm-up. While both warm-up programs yielded positive outcomes for professional male cyclists, the FIFA 11 + warm-up program demonstrated superior effects on core muscle strength, balance, and exercise tolerance and injury prevention. These findings suggest that the FIFA 11 + warm-up may be a more effective addition to training routines for cyclists, offering enhanced performance and reduced injury risks compared to conventional warm-up.
Artificial Intelligence of Things (AIoT) edge computing has emerged as a critical enabler for consumer technology, easing the load on distribution grid networks through enhanced data transmission and processing capabilities. The Internet of Things (IoT), a modern network paradigm, connects devices using sensors and communication mediums to enable seamless information exchange. However, the limited computational capacity of edge nodes poses challenges in optimizing AIoT edge resources compared to cloud computing. To address this, a cloud-edge three-layer framework for task offloading and edge resource allocation is proposed in the context of consumer technology and distribution grids. This model incorporates random tasks, limited resources, unequal processing power, and high latency requirements. It features two key phases: a resource auction using a multi-round iterative process and compute offloading managed by a Deep Reinforcement Learning (DRL) approach. Enhanced algorithms such as Double DQN and Dueling DQN are integrated into the job offloading process to improve performance. Simulations validate the convergence of the task offloading algorithm and demonstrate that the proposed methods significantly enhance computational efficiency and resource utilization for edge nodes. These advancements offer promising solutions for the dynamic needs of consumer technology and future communication networks.
Journal of Software Evolution and Process · vol. 37 (1)
ABSTRACT Information System Security (ISS) is the primary economic lever for the global economy. It is the cornerstone for value generation, and its absence undeniably affects technology, people, and finances. The emergence of the worldwide information society has introduced fresh economic and legal challenges attributed to the surge in Internet utilization and advancements in the digital economy. Ensuring the security of advancements within information systems has emerged as a primary concern in propelling the evolution of information processes within the software development industry. This study aims to develop and propose a Fuzzy Analytic Hierarchy Process (Fuzzy‐AHP) framework to enhance decision‐making for software maintenance and deployment in ISS. This framework aims to provide a systematic, flexible method for evaluating and prioritizing multiple conflicting criteria under conditions of uncertainty. The study initially adopts an empirical survey to identify software security maintenance and deployment risks and their practices for ISS organizations. Then adopts the Fuzzy‐AHP method to handle the imprecision of expert judgments and organizes decision‐making into a hierarchical structure. The framework is applied to evaluate key criteria related to software maintenance and deployment, including security risks, system performance, operational costs, and compliance requirements. Data from 50 ISS experts were collected and used to validate the framework. The paper identifies 52 security risks in maintenance and deployment (SRMD) processes in ISS and also identified 139 best practices for ensuring security, including regular updates, patch management, and adherence to industry‐standard security protocols. The Fuzzy‐AHP framework effectively structured the decision‐making process by prioritizing criteria and sub‐criteria. The results demonstrated that the framework helps mitigate the subjective biases in expert judgment and provides a more balanced assessment of maintenance and deployment strategies. Prioritizing security risks and compliance emerged as key factors in the decision‐making process. The proposed Fuzzy‐AHP framework provides an innovative and adaptable solution for optimizing ISS organizations' software maintenance and deployment decisions. It addresses the complexity and uncertainty involved in such decisions, offering a transparent and structured approach that improves the accuracy and reliability of outcomes. Future research should focus on empirical validation of the framework in real‐world case studies and expand its application to other industries with similar decision‐making needs.
software maintenancesoftware deploymentinformation security systemsfuzzy analytic hierarchy process
BACKGROUND: Topoisomerase II (Topo II) remains a validated target for anticancer therapy, with many clinically used agents acting via DNA intercalation and enzyme inhibition. However, their clinical use is limited by severe toxicity and resistance. In this study, we investigate aotaphenazine, a rare hydrophenazine derivative isolated from Streptomyces sp. IFM 11694 as a potential novel Topo II inhibitor with selective anticancer activity. METHODS: Molecular docking and 400 ns molecular dynamics (MD) simulations were employed to evaluate aotaphenazine's binding mode within the DNA-Topo II complex (PDB: 3QX3). MM-GBSA calculations quantified interaction energetics, while ProLIF and PLIP analyses detailed the interaction patterns. Topo II inhibition was assessed via in vitro enzymatic assays. Cytotoxicity (MTT) assays were conducted against a panel of human cancer and normal cell lines. Flow cytometry was used to evaluate apoptosis and cell cycle progression in MDA-MB-231 cells. RESULTS: aotaphenazine demonstrated a docking binding energy of -19.12 kcal/mol and remained stably intercalated within the DNA groove during MD simulations. MM-GBSA analysis showed a total binding free energy of -29.81 kcal/mol, driven primarily by van der Waals forces. Interaction profiling identified consistent π-stacking with Cyt8 and Thy9, and strong binding contributions from Ade12 and Gua13. Enzymatic assays confirmed Topo II inhibition with an IC50 of 45.01 nM, comparable to doxorubicin (30.16 nM). In vitro cytotoxicity analysis revealed moderate activity across cancer cell lines (IC50 = 26.30-54.35 µM) and significantly reduced toxicity in normal WI-38 and WISH cells (IC50 = 69.86 µM and 84.72 µM, respectively). Flow cytometry showed that aotaphenazine induced early (20.98%) and late apoptosis (42.80%), along with S-phase cell cycle arrest (43.99%) and a marked reduction in the G2/M population in MDA-MB-231 cells. CONCLUSION: aotaphenazine exhibits a compelling combination of Topo II inhibition, DNA intercalation, and selective anticancer activity, supported by both computational modeling and biological validation. Its lower cytotoxicity toward normal cells and ability to induce apoptosis and cell cycle arrest suggest strong therapeutic potential. These findings establish aotaphenazine as a promising lead compound for the development of safer and more selective Topo II-targeting anticancer agents.
topoisomerase II inhibitionDNA intercalationanticancer activitynatural product isolation